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Abstract: The anti-CD20 mAb Rituximab has revolutionized lymphoma therapy, in spite of a number
of unresponsive or relapsing patients. Immunotoxins, consisting of toxins coupled to antibodies, are
being investigated for their potential ability to augment Rituximab efficacy. Here, we compare the
anti-tumor effect of high- and low-molecular-weight Rituximab/saporin-S6 immunotoxins, named
HMW-IT and LMW-IT, respectively. Saporin-S6 is a potent and stable plant enzyme belonging
to ribosome-inactivating proteins that causes protein synthesis arrest and consequent cell death.
Saporin-S6 was conjugated to Rituximab through an artificial disulfide bond. The inhibitory activity
of HMW-IT and LMW-IT was evaluated on cell-free protein synthesis and in two CD20+ lymphoma
cell lines, Raji and D430B. Two different conjugates were separated on the basis of their molecular
weight and further characterized. Both HMW-IT (dimeric) and LMW-IT (monomeric) maintained a
high level of enzymatic activity in a cell-free system. HMW-IT, thanks to a higher toxin payload and
more efficient antigen capping, showed stronger in vitro anti-tumor efficacy than LMW-IT against
lymphoma cells. Dimeric HMW-IT can be used for lymphoma therapy at least for ex vivo treatments.
The possibility of using HMW-IT augments the yield in immunotoxin preparation and allows the
targeting of antigens with low internalization rates.
Keywords: B-cell lymphomas; immunotherapy; immunotoxin; ribosome-inactivating protein;
Rituximab; Saporin-S6
1. Introduction
CD20 (B1) is a membrane protein highly expressed by mature B lymphocytes. This cluster
determinant represents an excellent target for monoclonal antibody (mAb)-based immunotherapy
because of several favorable properties: (i) it is expressed on approximately 90% of B-cell non-Hodgkin’s
lymphomas (NHLs); (ii) it is not expressed on B cell precursors nor on other tissues; (iii) it is widely
expressed on the cell membrane; and (iv) it is not normally shed from the cell [1]. Rituximab is an
anti-CD20 mouse-human chimeric mAb that has proven to be effective for the treatment of CD20+
NHLs and chronic lymphocytic leukemia. This mAb can activate different cell death mechanisms,
primarily complement-dependent cytotoxicity (CDC), but also antibody-dependent cell cytotoxicity
(ADCC) and, to a lesser extent, apoptosis. Moreover, Rituximab can raise the T-cell response against
malignant clones [2–4].
Rituximab was the first antibody approved by the US FDA for the treatment of
recurrent/refractory follicular NHL. Since 1997, Rituximab as a single agent or in combination with
chemotherapy has revolutionized lymphoma therapy. Unfortunately, Rituximab is not effective for all
patients, and another problem arises from an acquired resistance to Rituximab that has been reported
for some patients [5].
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Therefore, various strategies have been prospected to achieve higher anti-tumor response and
longer remission duration. For example, Rituximab efficacy has been augmented by conjugation
to active moieties, such as radionuclides (radioimmunoconjugates) [6], toxic enzymes or lectins
(immunotoxins, ITs) [7,8], and drugs (immunoconjugates) [9,10].
An increase in the efficacy of Rituximab against human B-cell lymphoma xenografts was obtained
after conjugation to the anti-cancer drug calicheamicin in preclinical models with either nude or SCID
mice [9]. Rituximab-conjugated to doxorubicin-loaded microbubbles, combined with ultrasound
irradiation, were tested on Raji lymphoma cells. In this case, the increase in toxicity was encouraging
but still modest [10].
Better results were achieved with radioimmunoconjugates, which were obtained by radiolabeling
Rituximab and other anti-CD20 mAbs with 131I or 90Y, but, despite the good results reported in the
preliminary studies, most treated patients relapsed [6].
The anti-tumor effect of mAbs may also be increased via the conjugation to a toxic molecule, thus
obtaining chimeric proteins, called immunotoxins, in order to add cytotoxic properties to the specificity
of the antibody. Both bacterial and plant toxins have been used to obtain immunotoxins [11–14].
Among plant toxins, the most utilized for conjugates are ribosome-inactivating proteins (RIPs), which
can mainly be divided into the following two groups: type 1, consisting of a single-chain protein with
enzymatic activity, and type 2, consisting of an enzymatic A-chain linked to a B-chain with lectin
properties [15]. RIPs are a class of enzymes that is widely distributed in the plant kingdom. RIP activity
was first identified as rRNA N-glycosylase (EC 3.2.2.22), which specifically removes the A4324 adenine
residue inside the universally conserved GAGA sequence on the ricin/sarcin region of the 28S rRNA
in the 60S subunit of the rat ribosome. The adenine removal impairs ribosomes in an irreversible way,
resulting in the inhibition of protein synthesis [15]. RIPs also show in vitro N-glycosylase activity on
other substrates, such as DNA, mRNA, tRNA, and poly(A) [16,17]. For this reason, the RIPs have been
proposed to be classified as a polynucleotide: adenosine glycosylases [18,19].
Saporin-S6 is a potent and stable type-1 RIP that is often used to construct immunotoxins [7,13]
and has also been tested in clinical trials [12]. The ability to act on different substrates makes saporin-S6
able to kill cells by triggering several mechanisms of death such as apoptosis and necroptosis [20],
and autophagy and oxidative stress [21], as already reported for other RIPs [22]. Saporin-S6 has also
been detected in the nucleus of intoxicated cells, and early DNA strand breaks were simultaneously
observed, suggesting a direct action on nuclear DNA [23].
In a previous study, we conjugated Rituximab to saporin-S6 and evaluated its anti-tumor
activity in NHL cells. This immunotoxin was extremely cytotoxic to target cells. The conjugate
also induced apoptosis in 95% of treated cells at a concentration of 10 nM. The co-administration with
the chemotherapy drug fludarabine increased the cytotoxicity of Rituximab/saporin-S6 and caused
the complete elimination of the malignant population [24].
Further, Flavell and coworkers [25] showed that the combination of Rituximab + anti-CD19
BU12/Saporin-S6 immunotoxin had a strong in vitro cytotoxic effect on Ramos cell line. In SCID-Ramos
mice, the combination of the immunotoxin and Rituximab led to the complete survival of all animals
that were disease-free at day +120.
In this study, we compare the in vitro anti-tumor activity of two conjugates consisting of
anti-CD20 Rituximab and saporin-S6, characterized by a different number of mAb and RIP molecules
linked together.
2. Results
The RIP saporin-S6 was conjugated to the anti-CD20 mAb Rituximab through an artificial disulfide
bond. The optimal derivatization condition for Rituximab, to obtain a dimeric immunotoxin, was
reached with 0.5 mM 2-iminothiolane, which yielded 3.66 thiol groups inserted per molecule. For
saporin-S6 0.94 thiol groups per molecule were inserted using the linker 2-iminothiolane at a 1 mM
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concentration. The immunoconjugate was purified by gel filtration chromatography, and the fractions
corresponding to the different peaks were pooled and analyzed by SDS–PAGE (Figure 1).Toxins 2016, 8, 192  3 of 12 
 
 
Figure 1.  (a) Elution profile of gel‐filtration  chromatography on a Sephacryl S‐200 HR  column of 
Rituximab/saporin‐S6 conjugate. The blue line represents the A280, and the red dashed line represents 
the radioactivity of the eluted fractions. The fractions corresponding to the peaks were pooled and 
indicated with  capital  letters:  (A) high‐molecular‐weight  immunotoxin  (HMW‐IT)  (blue area);  (B) 
low‐molecular‐weight  immunotoxin  (LMW‐IT)  (green area);  (C)  free Rituximab;  (D)  trimmers;  (E) 
dimers  and  (F) monomers of  saporin‐S6.  (b) Analysis of  fractions  corresponding  to HMW‐IT  (1), 
LMW‐IT (2), and unconjugated Rituximab (3) by SDS–PAGE under non‐reducing conditions on a 4%–
15% PhastGel. Standard molecular weights (St) are expressed in kDa. 
We separated two different types of conjugates, a low‐molecular‐weight immunotoxin (LMW‐
IT)  and  high‐molecular‐weight  immunotoxin  (HMW‐IT). The  average molecular weight  and  the 
possible composition of the two conjugates were calculated on the basis of the elution volume, SDS‐
PAGE analysis, and RIP‐to‐antibody ratio, estimated by the 125I‐RIP radioactivity and the A280. LMW‐
IT is a mixture of 210 kDa average molecular weight conjugates composed of one mAb and one or 
more RIP molecules. HMW‐IT consists of a complex of two antibodies and more RIP molecules, with 
a 510 kDa average molecular weight (Figure 2). 
 
Figure 2. Possible  structure of  the most  represented molecular  species of LMW‐IT and HMW‐IT, 
generated from Rituximab chemical conjugation to saporin‐S6. 
The final yields of conjugated mAb and RIP were 53% and 9%, respectively (Table 1). 
Table 1. Characteristics of low‐ and high‐molecular‐weight Rituximab/saporin‐S6 immunotoxins. 
Cnjugates  RIP/mAb Molar Ratio  Average Mw (kDa) IC50 1 (M × 10−11)
Yield (%) 2 
mAb  RIP 
LMW  1.93  210  7.31  37  5 
HMW  3.60  510  19.9  16  4 
1 Concentration causing 50% inhibition of protein synthesis in a cell‐free system (rabbit reticulocyte 
lysate). The IC50 of native saporin‐S6 is 5.24 × 10−11 M. 2 Amount of mAb and ribosome‐inactivating 
protein  (RIP)  recovered  in  the  conjugates,  each  expressed  as  a percentage of  the  starting protein 
amount. 
After conjugation, for both immunotoxins, we investigated whether saporin‐S6 maintained its 
enzymatic  activity,  evaluating  the  inhibition  of  protein  synthesis  in  a  cell‐free  system  (rabbit 
reticulocyte  lysate).  This  test  showed  that  protein  synthesis  was  efficiently  inhibited  by  both 
Figure 1. (a) Elution profile of gel-filtration chromatography on a Sephacryl S-200 HR column of
Rituximab/saporin-S6 conjugate. The blue line represents the A280, and the red dashed line represents
the radioactivity of the eluted fractions. The fractions corresponding to the peaks were pooled
and indicated with capital letters: (A) high-molecular-weight immunotoxin (HMW-IT) (blue area);
(B) low-molecular-weight immunotoxin (LMW-IT) (green area); (C) free Rituximab; (D) trimmers;
(E) dimers and (F) monomers of saporin-S6. (b) Analysis of fractions corresponding to HMW-IT (1),
LMW-IT (2), and unconjugated Rituximab (3) by SDS–PAGE under non-reducing conditions on a
4%–15% PhastGel. Standard molecular weights (St) are expressed in kDa.
We separated two different ypes of conjugates, a low-molecular-weight immunotoxin (LMW-IT)
and high-m lecular-weight immunotoxin (HMW-IT). The averag molecular weight and the possible
composition of the two conjugates were calculate on t e basis of the elut on volume, SDS-PAGE
analysis, and RIP-to-antibody ratio, estimated by the 125I-RIP radioactivity and the A280. LMW-IT is a
mixture of 210 kDa average molecular weight conjugates composed of one mAb and one or more RIP
molecules. HMW-IT consists of a complex of two antibodies and more RIP molecules, with a 510 kDa
average molecular weight (Figure 2).
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Figure 2. Possible structure of the most represented molecular species of LMW-IT and HMW-IT,
generated from Rituximab chemical conjugation to saporin-S6.
The final yields of conjugated mAb and RIP were 53% and 9%, respectively (Table 1).
Table 1. Characteristics of low- and high-molecular-weight Rituximab/saporin-S6 immunotoxins.
Cnjugates RIP/mAb Molar Ratio Average Mw (kDa) IC50 1 (M ˆ 10´11) Yield (%)
2
mAb RIP
LMW 1.93 210 7.31 37 5
HMW 3.60 510 19.9 16 4
1 Concentration causing 50% inhibiti of protein synthesi in a cell-fr e system (rabbit reticulocyte lysate).
The IC50 of native saporin-S6 is 5.24 ˆ 10´11 M. 2 Amount of mAb and ribosome-inactivating protein (RIP)
recovered in the conjugates, each expressed as a percentage of the starting protein amount.
Toxins 2016, 8, 192 4 of 12
After conjugation, for both immunotoxins, we investigated whether saporin-S6 maintained
its enzymatic activity, evaluating the inhibition of protein synthesis in a cell-free system (rabbit
reticulocyte lysate). This test showed that protein synthesis was efficiently inhibited by both conjugates.
The LMW-IT showed an IC50 of 7.31 ˆ 10´11 M, which was comparable to that of native saporin-S6
(5.24 ˆ 10´11 M). The HMW-IT showed an IC50 of 19.9 ˆ 10´11 M, and this value was not significantly
higher than that calculated for the LMW-IT (p = 0.082, as calculated by ANCOVA/Bonferroni test),
demonstrating that HMW-IT also maintained very good cell-free protein synthesis inhibitory activity.
By flow cytometry analysis, we demonstrated that the derivatization and conjugation procedures
did not alter the mAb binding affinity. As compared to Rituximab, the LMW-IT maintained the same
affinity for the CD20 antigen, while the HMW-IT showed an almost doubled antigen-binding property
(Figure 3a). The specificity for the CD20 antigen of the immunotoxins, as well as of the free mAb, is
demonstrated by the absence of binding to non-target MOLT-4 cells (CD20´) (Figure 3b).
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No binding was observed with unconjugated saporin‐S6. 
Figure 3. Cytofluorimetric analysis of Rituximab, HMW-IT, and LMW-IT binding on Raji (CD20+)
(a) and MOLT-4 (CD20´) (b) cells. Grey histograms indicate the cells incubated without the mAb or
immunotoxins. The fluorescence intensity, evaluated as FITC-A mean value, is also reported in the
table (c).
The binding of both HMW-IT and LMW-IT to the CD20 antigen, revealed by an anti-saporin-S6
antibody, was blocked by an excess of unconjugated Rituximab, thus indicating that the immunotoxins
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retained the immunospecificity and binding characteristics of Rituximab (Figure 4). No binding was
observed with unconjugated saporin-S6.Toxins 2016, 8, 192  5 of 12 
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(d). 
Cytotoxicity experiments were performed on  two CD20+  lymphoma cell  lines, namely D430B 
and Raji, by measuring protein synthesis  inhibition after 96 h. After conjugation with Rituximab, 
saporin‐S6 showed an increased cytotoxicity to target cells by 3 logs for HMW‐IT and 2 logs for LMW‐
IT, with IC50 values of 10−11 M and 10−10 M, respectively (Figure 5, Table 2). The HMW‐IT in both cell 
lines was  significantly more  active  than LMW‐IT. Protein  synthesis was  completely  inhibited by 
HMW‐IT at a 10−9 M concentration, whereas LMW‐IT had the same effect at a 10−8 M concentration. 
Free saporin‐S6 or a mixture of unconjugated Rituximab and saporin‐S6 were able to significantly 
inhibit protein synthesis only at a 10−8 M concentration, and it was not possible to calculate an IC50 
value. No inhibition was induced by free mAb. 
The specificity for CD20 of the two immunotoxins was investigated with two non‐target (CD20−) 
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Figure 4. Immunospecificity of the immunotoxins towards CD20 expressing cells (Raji) by
cytofluorometric analysis. The cells were incubated with HMW-IT and LMW-IT in the absence (b,c) or
in the presence (e,f) of 100-fold molar excess of Rituximab. The immunotoxins binding was detected
by rabbit antisera against saporin-S6, followed by an anti-rabbit FITC antibody. Control samples were
run with complete mediu alone (see Matherials and Methods) (a) or with saporin-S6 (d).
Cytotoxicity experiments were performed on two CD20+ lymphoma cell lines, namely D430B and
Raji, by measuring protein synthesis inhibition after 96 h. After conjugation with Rituximab, saporin-S6
showed an increased cytotoxicity to target cells by 3 logs for HMW-IT and 2 logs for LMW-IT, with
IC50 values of 10´11 M and 10´10 M, respectively (Figure 5, Table 2). The HMW-IT in both cell lines
was significantly more active than LMW-IT. Protein synthesis was completely inhibited by HMW-IT
at a 10´9 M concentration, whereas LMW-IT had the same effect at a 10´8 M concentration. Free
saporin-S6 or a mixture of unconjugated Rituximab and saporin-S6 were able to significantly inhibit
protein synthesis only at a 10´8 M concentration, and it was not possible to calculate an IC50 value. No
inhibition was induced by free mAb.
The specificity for CD20 of the two immunotoxins was investigated with two non-target (CD20´)
cell lines, MOLT-4 and Jurkat. In both cases, the cytotoxicity of HMW-IT and LMW-IT was not
increased in comparison with the mixture of unconjugated Rituximab and saporin-S6, or to the RIP
alone. In any case, IC50 values were higher than the maximum tested concentration (10´8 M) (Table 2).
The visual inspection of Raji cells treated with immunotoxins showed morphological features
characteristic of apoptosis, including cell shrinkage, cell membrane budding, and cytoplasmic
condensation (Figure 6). The morphology of Raji cells treated with saporin-S6 in the same conditions
of immunotoxins did not differ from control cultures.
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Figure 5. Cell protein synthesis inhibition assay. D430B and Raji cells were treated with HMW-IT
(square), LMW-IT (triangle), free saporin-S6 (white circle) or a mixture of unconjugated Rituximab and
saporin-S6 (black circle). The cells (5 ˆ 103) were seeded in 96-well plates in a total volume of 200 µL of
complete medium (see Matherials and Methods) containing various concentrati ns of subst nces. After
96 h of incubatio and a further 6 h with [3H]-leucine, th incorporated radioactivity was d termined.
The results are the means of two independent experiments, each performed in triplicate. SD was <10%.
Data were analyzed by the ANCOVA/Bonferroni test. The inhibition of protein synthesis by HMW-IT
differed significantly (p < 0.001) from that by LMW-IT. Both immunotoxins significantly inhibited
protein synthesis with respect to the free RIP and mixture (p < 0.0001).
Table 2. Effects of HMW-IT and LMW-IT on cell protein synthesis.
Tested substances
C 20+ Target Cells CD20´ not Target Cells
D430B Raji MOLT-4 Jurkat
IC50 (M) 1
HMW-IT 2.93 ˆ 10´11 2.26 ˆ 10´11 >10´8 >10´8
LMW-IT 1.98 ˆ 10´10 1.52 ˆ 10´10 >10´8 >10´8
Saporin-S6 >10´8 >10´8 >10´8 >10´8
Saporin-S6 + Rituximab >10´8 >10´8 >10´8 >10´8
1 The IC50 of the immunotoxins refers to the RIP content.
Toxins 2016, 8, 192  6 of 12 
 
 
Figure 5. Cell protein synthesis  inhibition assay. D430B and Raji cells were  treated with HMW‐IT 
(square), LMW‐IT (triangle), free saporin‐S6 (white circle) or a mixture of unconjugated Rituximab 
and saporin‐S6 (black circle). The cells (5 × 103) were seeded in 96‐well plates in a total volume of 200 
μL  of  complete  medium  (see  Matherials  a d  Methods)  conta ning  various  concentration   of 
substances. After 96 h of incubation and a further 6 h with [3H]‐leucine, the incorporated radioactivity 
was determined. The  results  are  the means  of  two  independent  experiments,  each performed  in 
triplicate.  SD was  <10%. Data were  analyzed  by  the ANCOVA/Bonferroni  test. The  inhibition  of 
protein  synthesis  by  HMW‐IT  differed  significantly  (p  <  0.001)  from  that  by  LMW‐IT.  Both 
immunotoxins significantly inhibited protein synthesis with respect to the free RIP and mixture (p < 
0.0001). 
Table 2. Effects of HMW‐IT and LMW‐IT on cell protein synthesis. 
Tested substances 
CD20+ Target Cells CD20− not Target Cells 
D430B Raji OLT‐4 Jurkat 
IC50 (M) 1
HMW‐IT  2.93 × 10−11 2.26 × 10−11 >10−8  >10−8 
LMW‐IT  1.98 × 10−10 1.52 × 10−10 >10−8  >10−8 
Saporin‐S6  >10−8  >10−8  >10−8  >10−8 
Saporin‐S6 + Rituximab  >10−8  >10−8  >10−8  >10−8 
1 The IC50 of the immunotoxins refers to the RIP content. 
 
 
Figure 6. Morphology of Raji cells assessed by phase contrast microscopy. Cells were treated for 96 h
with 10´9 M HMW-IT or LMW-IT or saporin-S6. Control cultures (Ctrl) were grown in the absence of
immunotoxin or saporin-S6. Magnification: 400ˆ.
Toxins 2016, 8, 192 7 of 12
3. Discussion
In the last twenty years, thousands of lymphoma patients have benefited from Rituximab’s
anti-tumor activity [26]. Despite the successes reported for Rituximab, some patients do not respond
to the therapy, and others acquire resistance to Rituximab after the first series of treatments [5]. To
explain the mechanisms of this resistance, different alterations in host immunologic factors have been
assumed, such as (i) CDC unresponsiveness due to altered expression of CD46, CD55, and CD59
(complement-regulatory proteins) on tumor cells; (ii) ADCC resistance due to changes in the lipid raft
and FcγRIIIa polymorphisms, causing failed recognition of the CD20/antibody complex by effector
cells; (iii) selection of apoptosis resistant clones as a consequence of repeated exposure to Rituximab;
and (iv) selection of CD20´ tumor clones [27,28].
In addition to CDC and ADCC, it has been reported that Rituximab can directly trigger cell
death by apoptosis. However, a low percentage of CD20+ cells undergo apoptotic death after the
binding of Rituximab to its target antigen [2,29]. To augment the antibody ability to induce apoptosis
in CD20 cells, different strategies have been exploited, mainly involving the crosslinking of more CD20
receptors on the surface of lymphoma B cells [30].
An enhancement of the pro-apoptotic action of Rituximab was obtained by hypercross-linking
Rituximab with anti-human or anti-mouse immunoglobulins [31]. Moreover, a two-step therapeutic
approach has recently been described. This method is based on the administration of an anti-CD20 Fab’
antibody linked to a single-stranded oligonucleotide, followed by a complex consisting of multiple
copies of the complementary oligonucleotide, linked to a linear polymer backbone. The consecutive
administration of these drug-free components was proven to mediate CD20 crosslinking and to
enhance apoptosis both in vitro and in vivo [32,33].
Ghetie and coworkers [34] proposed that CD20 capping could also be improved using Rituximab
homodimers. They observed that homodimers, but not monomers, of Rituximab induced both
apoptosis and necrosis of several B-lymphoma cell lines. Homodimers induced 33% apoptosis in the
Ramos cell line, compared with 32% obtained with Rituximab monomers followed by goat anti-mouse
Ig, and both values were significantly higher than that obtained with Rituximab monomers (6%
of apoptotic cells). This enhanced effect can be attributed to the greater avidity of homodimers
that causes both an increase in the cross-linking of adjacent CD20 antigens and a lower antigen
dissociation of the complex. Moreover, in vivo, this one-step procedure is certainly simpler to apply
than a two-step procedure.
Starting from the above observations, in this study, we compared the in vitro activity of two
Rituximab/saporin-S6 immunotoxins, characterized by a different number of mAb and RIP molecules
linked together. In previous studies, an ideal immunotoxin was considered to be constituted by
an average of one molecule of antibody linked to one-two RIP molecules. This type of conjugate,
characterized by two antigen binding sites, was defined here as LMW-IT.
Previous studies evaluated the efficacy of immunotoxins containing a variable number of RIP
molecules on different cell targets [35–37]. These works reported that the number of inserted RIP
molecules was correlated to increased immunotoxin cytotoxicity, although in some cases with a
reduction of antigen binding capacity.
In this research, we investigated a different approach; in addition to the LMW-IT, we purified a
HMW-IT that is characterized by four antigen-binding sites. Increasing the mAb and/or RIP number
of thiol groups inserted, it was possible to obtain both the LMW-IT and the HMW-IT in the reaction
mixture. The HMW-IT is characterized by a higher avidity for CD20 and a higher toxin payload
compared with the LMW-IT. Accordingly, the cytofluorimetric analysis showed higher fluorescence
intensity for HMW-IT- than for LMW-IT-binding to CD20+ Raji cells. Additionally, through flow
cytometry analyses, we demonstrated that immunospecificity was retained for both types of construct.
This was established by experiments of immunotoxin binding to target (CD20+) and non-target
(CD20´) cells and by competition binding experiments with an excess of unconjugated Rituximab.
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In cell-free experiments, the LMW-IT maintained an almost unaltered capability to inhibit protein
synthesis in a cell-free system compared to saporin-S6. Under the same experimental conditions,
the HMW-IT showed a higher, even if not significant, IC50 value, corresponding to lower enzymatic
activity than LMW-IT. This loss of enzymatic activity for the HMW-IT is probably due to the fact that it
is composed of a larger number of RIP molecules with two chemically inserted SH groups. A high
derivatization degree of saporin-S6 leads to alterations of the three-dimensional toxin structure with
consequent reduction of its affinity for the ribosomal substrate.
In cell experiments, both Rituximab/saporin-S6 conjugates showed a strong effect on the two
CD20+ lymphoma-derived cell lines, causing a complete block of protein synthesis at a concentration
significantly higher for LMW-IT than for HMW-IT. In addition, the immunospecificity of immunotoxins
was demonstrated by the lack of cytotoxicity for CD20´ cell lines.
Though HMW-IT was less active than LMW-IT in cell-free experiments, in both cell lines it
showed a stronger effect. This could be explained by the higher avidity toward the CD20 antigen (four
antigen binding sites of the HMW-IT vs two of the LMW-IT) with a consequently better internalization
efficiency that could balance the lower affinity of the toxic molecule for the ribosomal substrate.
In agreement with the results reported for Rituximab homodimers, HMW-IT (which can be
considered a homodimer immunotoxin) showed a significant increase in anti-tumor activity. This
indicates that the increased number of mAb per immunotoxin molecule leads to a more efficient
internalization by enhancing CD20 capping. This, together with the higher toxic payload of HMW-IT,
results in a large amount of toxin being delivered inside the cell, thus increasing the lethal effect.
4. Conclusions
Experiments carried out in our laboratory showed that the HMW-IT has better anti-tumoral
features than the LMW-IT, suggesting a possible use in lymphoma therapy, at least for ex vivo treatments.
The possibility of utilizing both high- and low-molecular-weight conjugates strongly augments the
yield in the preparation of chemically formulated immunotoxins. Moreover, the potential of enhancing
the endocytosis of the immunotoxin by using a dimeric HMW molecule opens up the possibility of
also utilizing antigens with a low internalization rate. However, in view of a possible clinical use,
LMW-IT might penetrate better than HMW-IT into the tumor mass because of the smaller size and
would have greater access to the CD20 antigen on neoplastic cells. Further experiments in animal
models are necessary to establish the possible therapeutic value of the HMW-ITs.
5. Materials and Methods
5.1. Immunotoxin Preparation
Rituximab (anti-human CD20 mAb) was purchased from Roche (Milan, Italy). The type-1
RIP saporin-S6, from the seeds of Saponaria officinalis, was purified as previously described [38].
Saporin-S6 was labeled with 125I using the Iodogen reagent (Pierce Chemical Co., Catex, Dallas, TX,
USA) according to the manufacturer’s instructions.
The RIP and the mAb were chemically linked through a disulfide bond between the inserted
thiol groups, as already described [39,40]. Briefly, Rituximab and saporin-S6, containing a trace of
125I-RIP, were modified by adding 2-iminothiolane. Thiol groups were inserted into each molecule
by an imidoester reaction between 2-iminothiolane and the primary amino groups of the proteins.
The derivatized RIP was reduced with 20 mM 2-mercaptoethanol, filtered through a Sephadex G25
column (GE-Healthcare, Buckinghamshire, UK), and then mixed with the derivatized mAb, in a
10:1 molar ratio. The mixture was allowed to react for 16 h at room temperature. The resulting
high-molecular-weight immunotoxin (HMW-IT) and low-molecular-weight immunotoxin (LMW-IT)
were separated from the unreacted reagents and from saporin-S6 homopolymers by gel filtration on a
Sephacryl S200 high-resolution column (100 cm ˆ 2.5 cm) (GE-Healthcare), equilibrated and eluted
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with phosphate-buffered saline (PBS, 0.14 M sodium chloride in 5 mM sodium phosphate buffer,
pH 7.4) [24].
The immunotoxins were analyzed by SDS-PAGE under non-reducing conditions. Proteins
were incubated in sample buffer (40 mM Tris-HCl pH 6.8, 2% SDS, 0.005% bromophenol blue),
containing 1 mg/mL iodoacetamide, for 30 min at room temperature, analyzed on a 4%–15% PhastGel
gradient (GE-Healthcare), and then stained with Coomassie brilliant blue, as described in [24].
The RIP-to-antibody ratio in the conjugates was estimated from the 125I-RIP radioactivity and
from the protein concentration calculated from the A280. The radioactivity enabled the calculation
of the saporin-S6 contribution to the A280 of the conjugate. By subtracting this amount from the
total absorbance of each immunotoxin, the Rituximab contribution to the A280 of the conjugates was
calculated. Then, the absorbance of each protein was divided for the respective molar extinction
coefficient to obtain the relative concentration of RIP and mAb in the two immunotoxins [41].
5.2. Cell Lines
The activity of the immunotoxins was assayed on the CD20+ cell lines Raji, derived from a Burkitt’s
lymphoma (ATCC number CCL-86™, and D430B, an Epstein Barr virus infected B cell line [42]. The
CD20´ MOLT-4 (ATCC number CRL-1582™) and Jurkat (ATCC number TIB-152™) cell lines were
used as non-target cells. All the cell lines were from long-term culture of our department.
Cells were maintained in RPMI 1640 medium, supplemented with 10% heat-inactivated fetal
bovine serum (FBS), 2 mM L-glutamine, 100 U/mL penicillin, and 100 µg/mL streptomycin, (hereafter
named complete medium), in humidified air with 5% CO2 at 37 ˝C. Viability was checked before each
experiment by trypan blue dye exclusion. All medium and reagents for cell cultures were purchased
from Sigma (Sigma-Aldrich, St. Louis, MO, USA).
5.3. Protein Synthesis Inhibition Assays
The inhibitory activity of the immunotoxins on cell-free protein synthesis was evaluated with a
rabbit reticulocyte lysate as described in [43]. Immunotoxins were previously reduced with 20 mM
2-mercaptoethanol for 30 min at 37 ˝C, appropriately diluted, and then added to a reaction mixture.
Each experiment was carried out in duplicate. The concentration of immunotoxin, expressed
as RIP content, causing 50% inhibition of leucine incorporation (IC50) was calculated by linear
regression analysis.
The cytotoxicity of the immunotoxin was evaluated from the inhibition of cellular 3H-leucine
incorporation. Cells (5 ˆ 103/well) were seeded in 96-well microtiter plates (Falcon, Becton Dickinson,
Franklin Lakes, NJ, USA) in 100 µL of complete medium, and 100 µL of Rituximab-containing
immunotoxin was added to final concentrations ranging from 10´13 to 10´8 M. Concentrations are
expressed as immunotoxin content. Control samples were run with RIP alone. After 96 h, cells were
washed, 5 kBq of L-[4,5-3H]leucine (Amersham) was added, and after a further 6 h, cells were harvested
with an automatic cell harvester (Skatron Instruments, Lier, Norway) onto glass-fiber diskettes. The
radioactivity incorporated was determined as previously described [44,45].
The morphological analysis of the treated cells was conducted through phase-contrast microscopy
directly in 96-well plates using a digital camera from Motic Microscopes (Xiamen, Fujian, China). The
presence of cellular morphological changes was examined in Raji cells treated for 96 h with 10´9 M
HMW-IT and LMW-IT.
5.4. CD20 Affinity Cytofluorimetric Experiments
Rituximab affinity for CD20 antigen was evaluated by indirect immunofluorescence. Cells
(5 ˆ 105 in complete medium) were treated with Rituximab or immunotoxins, at the final concentration
of 10´8 M as described in [24]. After cell fixation with 70% ethanol, the CD20 binding of Rituximab,
HMW-IT, and LMW-IT was assessed through flow cytometry on a FACSAria BD Analyzer using
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FACSDiva software (Becton, Dickinson and Company, FranklinLakes, NJ, USA). The intensity of
fluorescence, evaluated as FITC-A mean value, was used as the measure of the binding capability.
In the Rituximab competition experiments, cells (5 ˆ 105 in complete medium) were collected
into round-bottom tubes at 4 ˝C and incubated with 50 µL of Rituximab at 10´6 M concentration
or with 50 µL of PBS, 1% FCS. After 30 min, cells were centrifuged at 500ˆ g for 5 min at 4 ˝C and
treated for 30 min at 4 ˝C with free saporin-S6, HMW-IT or LMW-IT, at a final concentration of 10´8 M.
Control samples were run with complete medium alone. After a wash in PBS containing 1% FCS, cells
were incubated for 30 min at 4 ˝C with 50 µL of rabbit antisera against saporin-S6 (1:100). After a
further wash, 50 µL of anti-rabbit FITC antibody were added for 30 min at 4 ˝C. After three washes
in cold PBS, 1% FCS, the samples were fixed with 70% cold ethanol. The fluorescence intensity was
assessed as above described.
5.5. Statistical Analyses
The statistical analyses for the in vitro experiments were conducted using XLSTAT-Pro software,
version 6.1.9 (Addinsoft, New York, NY, USA, 2003). The results are given as the means ˘ S.D.
The data were analyzed using ANCOVA and ANOVA tests, with Bonferroni’s correction for
multiple comparisons.
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Abbreviations
The following abbreviations are used in this manuscript:
mAb monoclonal antibody
NHL non-Hodgkin’s lymphoma
CDC complement-dependent cytotoxicity
ADCC antibody-dependent cellular cytotoxicity
RIP ribosome-inactivating protein
HMW-IT high-molecular-weight immunotoxin
LMW-IT low-molecular-weight immunotoxin
PBS phosphate-buffered saline
FBS fetal bovine serum
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